Assembly Biosciences, Inc.
ASMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001426800
In the last 90 days, Assembly Biosciences, Inc. insiders filed 0 open-market purchases and 4 sales; 93 institutions reported holding it in 13F filings for Q2 2026, worth $514.8M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:07 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $6.12M (8.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 19, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 22, 2023 | Mar 10, 2022 |
| Revenue | $72.3M | $28.5M | $7.16M | – | $6.25M |
| Operating expenses | $84.4M | $73.9M | $71.8M | $94.1M | $138.9M |
| Research and development | $64.8M | $55.9M | $48.9M | $70.0M | $68.5M |
| Selling, general and administrative | $19.6M | $18.0M | $22.9M | $24.1M | $28.8M |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | -$132.7M |
| Income tax | $0 | $330.0K | $33.0K | $0 | -$2.53M |
| Net income | -$6.12M | -$40.2M | -$61.2M | -$93.1M | -$129.9M |
| EPS, basic | $-0.55 | $-6.69 | $-13.38 | $-1.92 | – |
| EPS, diluted | $-0.55 | $-6.69 | $-13.38 | $-1.92 | – |
| Weighted shares, basic | 11.2M | 6.00M | 4.58M | 48.4M | – |
| Weighted shares, diluted | 11.2M | 6.00M | 4.58M | 48.4M | – |
| Margins and growth | |||||
| Operating margin | -16.8% | -159.3% | -902.5% | – | -2121.7% |
| Net margin | -8.5% | -140.9% | -854.8% | – | -2076.4% |
| Revenue growth, year over year | +153.5% | +298.2% | – | – | −92.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 19, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 22, 2023 | Mar 10, 2022 |
| Cash and equivalents | $58.5M | $38.3M | $19.8M | $52.4M | $45.6M |
| Accounts receivable | $974.0K | $0 | $43.0K | $944.0K | $336.0K |
| Total current assets | $254.5M | $115.5M | $133.8M | $97.0M | $154.2M |
| Property, plant and equipment | $221.0K | $284.0K | $385.0K | $743.0K | $1.14M |
| Total assets | $257.6M | $119.2M | $136.8M | $101.8M | $191.1M |
| Accounts payable | $1.17M | $585.0K | $461.0K | $2.49M | $2.66M |
| Total current liabilities | $48.8M | $47.8M | $39.2M | $16.3M | $16.1M |
| Total liabilities | $50.8M | $85.8M | $95.7M | $19.1M | $22.1M |
| Shareholders' equity | $206.8M | $33.4M | $41.1M | $82.7M | $168.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 19, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 22, 2023 | Mar 10, 2022 |
| Operating cash flow | -$41.1M | -$51.1M | $22.7M | -$84.5M | -$93.4M |
| Capital expenditures | $66.0K | $28.0K | $255.0K | $102.0K | $3.10M |
| Free cash flow | -$41.2M | -$51.1M | $22.5M | -$84.6M | -$96.5M |
| Depreciation and amortization | $129.0K | $129.0K | $450.0K | $498.0K | $466.0K |
| Stock-based compensation | $4.68M | $3.12M | $5.12M | $6.59M | $5.24M |
| Investing cash flow | -$113.5M | $40.2M | -$69.1M | $90.6M | $26.5M |
| Financing cash flow | $174.7M | $29.4M | $13.8M | $614.0K | $53.1M |
| Net change in cash | $20.1M | $18.5M | -$32.6M | $6.79M | -$13.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 6.5% | 10.9% | 71.5% | – | 83.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 7, 2026 | 20.4M | +165.4% | SEC |
| May 1, 2026 | 15.9M | +108.1% | SEC |
| Mar 13, 2026 | 15.9M | +111.4% | SEC |
| Nov 7, 2025 | 15.8M | +148.8% | SEC |
| Aug 1, 2025 | 7.67M | +20.9% | SEC |
| May 2, 2025 | 7.64M | +38.5% | SEC |
| Mar 14, 2025 | 7.50M | +36.9% | SEC |
| Nov 1, 2024 | 6.36M | −90.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-12 in Q1 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.